FDA Recall D-0153-2026
Zydus Pharmaceuticals (USA) Inc · Pennington, NJ
Class II Ongoing 204 days on record
Product
clomiPRAMINE Hydrochloride, Capsules, USP, 50 mg, packaged in a) 30-count bottles (NDC 16714-850-01), b) 90-count bottles (NDC 16714-850-02), c) 100-count bottles (NDC 16714-850-03), Rx only, Manufactured for: Northstar Rx LLC, Memphis, TN 38141, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India
Reason for recall
cGMP deviations: an observed Out of Specification of Nitrosamine Drug Substance-Related Impurities (NDSRIs), N-Nitroso Desmethyl-Clomipramine, above the FDA acceptable intake limit.
Recall record
- Recall number
D-0153-2026- Classification
- Class II
- Status
- Ongoing
- Voluntary or mandated
- Voluntary: Firm initiated
- Firm notification
- Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
- Distribution
- Nationwide in the US
- Recall initiated
- 2025-10-22
- Classified by FDA Center
- 2025-11-04
- FDA published
- 2025-11-12
- Recalling firm
- Zydus Pharmaceuticals (USA) Inc
- Firm location
- Pennington, NJ
Drug identification
- Brand name(s)
- CLOMIPRAMINE HYDROCHLORIDE
- Generic name(s)
- CLOMIPRAMINE HYDROCHLORIDE
- Manufacturer(s)
- Northstar Rx LLC.
- NDC(s)
16714-849, 16714-850, 16714-851- Route(s)
- ORAL
Operational response
Class II recalls indicate possible temporary or reversible health consequences. Remove affected lots from active dispensing. Segregate inventory. Check the firm’s recall notification for guidance on patient outreach.
For the official FDA enforcement record, see FDA's Recall Search.